Home
NewsNewsThe Florida Supreme Court has clarified that its statute on reproductive technology does not apply to At-Home Artificial Insemination.
The Florida Supreme Court went on to rule recently that a man who went on to offer his sperm to a couple for at-home artificial insemination did not automatically give up his paternal rights.
The 4-3 decision went on to determine that the previous legislation that surrounds artificial insemination only went on to apply to the use of assisted reproductive technology - ART, which is defined as procreative procedures involving the laboratory handling when it comes to human eggs or preembryos, says the ruling.
Apparently, the case in question goes on to involve Angel Rivera, who is a Florida man who went on to give his sperm to Ashley Brito and Jennifer Salas for use with an at-home artificial insemination kit.
Brito apparently gave birth to the child, and she, along with Salas, was listed as the parent of the child on the birth certificate. The couple went on to raise the child together for more than a year before separating, as per the ruling. Rivera then went on to file a petition in circuit court seeking to be recognized as the legal father of the child.
The court, however, denied this petition on the grounds that he went on to give up his paternal rights as per section 742.14, which states that the donor of any egg, sperm, or even pre-embryo, other than the commissioning couple or a father who has gone on to execute a preplanned adoption agreement as per s. 63.213, shall not be subject to the maternal or paternal rights and even obligations with regard to the donation or the resulting children.
In the decision made by the court, it said Rivera happened to be a sperm donor who had not met either of the two exceptions of relinquishment of the statute. Moreover, the court further said that the artificial insemination procedure, since it was not carried out in a clinical setting, does not alter the applicability of the statute.
Notably, the Second District also affirmed the ruling made by the circuit court.
apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.
Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.
TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.
CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.
Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.
UNC Fertility has announced its plans for Collaboration with IVI RMA North America to bring best clinical and operational best practices across the region, expanding access to cutting-edge fertility treatments and research.
Alife Health has secured FDA clearance for Embryo Predict, its AI-powered embryo assessment tool for IVF. Backed by a 440-patient, seven-center randomized clinical trial, the platform delivers data-driven embryo selection insights to embryologists across the U.S., Europe, and the U.K., addressing longstanding variability in clinical decision-making.
